Fig. 1: Study protocol and efficacy of the ANGPTL3 vaccine against circulating triglyceride levels in C57BL/6 J mice fed a normal diet.
From: Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine
a Schematic of vaccine design and vaccination methods. b Schematic showing vaccine injection protocol. c Circulating antibody titers in mice at 6, 20, 60, 62, 90, 92, and 105 weeks after the first E3 immunization. Values are reported as the serum dilution giving half-maximal binding (optical density: OD50%). p < 0.01 for interaction between week and E3 treatment (n = 11 per group). Portions of plots within dotted squares represent data referenced from our previous report related to the E3 vaccine4. d Non-fasting TG levels circulating in mice at 0, 6, 20, 60, 62, 90, 92, and 105 weeks after the first E3 immunization. p < 0.01 for interaction between week and E3 treatment (n = 11 per group). Portions of plots within dotted squares represent data referenced from our previous report related to the E3 vaccine4. c, d Results are presented as mean ± SEM. n.s. not significant. ∗p < 0.05 versus KLH (control) group. †p < 0.01 versus KLH (control) group.
